Diets containing blueberry extract lower blood pressure in spontaneously hypertensive stroke-prone rats

Kevin S Shaughnessy1, Ian A Boswall, Adam P Scanlan

  • 1Department of Biology, University of Prince Edward Island, Charlottetown, PEI, Canada C1A 4P3.

Insights

Blueberry (BB) consumption may help lower high blood pressure in rats by protecting the kidneys from oxidative stress, not through systemic antioxidant effects. This finding suggests a potential dietary strategy for managing hypertension.

Area of Science:

  • Cardiovascular Science
  • Nutritional Science
  • Nephrology

Background:

  • Oxidative stress in blood vessels and kidneys is a key factor in hypertension, a major risk for cardiovascular disease.
  • Blueberries (BB) are recognized for their rich antioxidant content.

Purpose of the Study:

  • To investigate the effects of blueberry-enriched diets on the development of hypertension in spontaneously hypertensive stroke-prone rats (SHRSP).
  • To determine if blueberry's antioxidant properties contribute to its potential antihypertensive effects.

Main Methods:

  • Eight-week-old normotensive rats and SHRSP were fed either a control diet or a diet with 3% freeze-dried blueberries for 8 weeks.
  • Systolic blood pressure (SBP) was measured regularly, and urine was collected to assess oxidative stress markers like F2-isoprostanes and kidney damage markers.

Main Results:

  • SHRSP consistently showed higher SBP than normotensive rats throughout the study.
  • Blueberry-fed SHRSP exhibited significantly lower SBP at weeks 4 (19% reduction) and 6 (30% reduction) compared to controls.
  • While blueberries did not alter systemic oxidative stress markers (urinary F2-isoprostanes), they reduced markers of renal oxidative stress, including proteinuria and kidney nitrites.

Conclusions:

  • A diet enriched with 3% blueberries may mitigate hypertension in SHRSP.
  • The antihypertensive effect appears linked to renal protection against oxidative damage rather than a systemic antioxidant mechanism.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...